UPDATED: Two deaths force MSK to hit the brakes on engineered T cell cancer ... FierceBiotech Six patients died of either disease relapse or progression, said MSK, while two patients died in remission from complications related to allogeneic bone marrow transplantation. An additional two patients died within two weeks of receiving a CAR-T cell ... |
